The Australian Translational Medicinal Chemistry Facility (ATMCF) is a purpose-designed, outward-facing, collaborative facility to support early stage medicinal chemistry-led drug discovery. Through application of expert advanced chemistry skills, we can increase potency, selectivity, and in vivo efficacy of your compounds, or of compounds we help you identify from the scientific or patent literature. ATMCF also provides expertise in high-throughput screening (HTS) hit selection, fragment-based drug discovery (FBDD), structure-based drug design and SAR guided optimization. ATMCF can collaborate through preclinical development, or can pass optimized compounds (or series) back to the partner as requested. ATMCF collaborates with researchers from universities, medical research institutes, government research agencies and industry.
Mission statement: To engage and collaborate with researchers from universities, medical research institutes, government research agencies and industry, to add value to early stage translational drug discovery. We are an outward-facing, collaborative medicinal chemistry facility to support early stage medicinal chemistry-led drug discovery.

Australia needs a Medicinal Chemistry Facility

- Recognition of the gap in early phase medicinal chemistry led to State (VSA) and Federal (EIF) investments in ATMCF to establish a purpose-built facility for translation of biological discoveries into value-added therapeutics.
- ATMCF is an essential element in the higher-level and broader Virtual Pharma Drug Development Network (VPDDN) being established and advanced by Therapeutic Innovation Australia (www.therapeuticinnovation.com.au).

Intellectual Property

- Owned by partner client – but we are open to shared risk models.
- We are well experienced working at the university and commercial interface and have a proven track record in bringing drugs into the clinic.
- We fully adhere to CDAs.

What we do:

- We optimize small molecules to make them more drug-like, potent, selective, efficacious, and in clear IP-space for patenting.
- We can collaborate through preclinical development, or we can pass optimized compounds (or series) back to the partner as requested.
- ATMCF has seamless access to SYNThesis med chem for CRO and other discovery needs.

Facility Highlights

- Purpose-designed facility; several fully equipped medicinal chemistry labs; analytical support lab.
- Onsite access to the Centre for Drug Candidate Optimisation for early ADME and PK studies (platforms.monash.edu/cdco).
- Partnered with Compounds Australia for access to screening libraries.

ATMCF – Operational Value Adding

Co-Director

Professor Jonathan Baell

Jonathan specializes in medicinal chemistry-led drug discovery with more than 20 years of experience.  
Phone: +61 (3) 9903 9044  
Email: jonathan.baell@monash.edu

Co-Director

Associate Professor Bernie Flynn

Bernie has over 20 years experience in drug discovery in industry and academia. His primary area of expertise is in medicinal chemistry and small-molecule drug design.  
Phone: +61 (3) 9903 9650  
Email: bernard.flynn@monash.edu

Platforms: platforms.monash.edu/atmcf